



NEWS RELEASE

Greystone Pharmaceuticals, Inc.

IMMEDIATE RELEASE
April 28, 2007

Contact: Marty Doyle
President
Greystone Pharmaceuticals, Inc.
(305) 206-1513

Greystone Pharmaceuticals, Inc. Announces Appointment of Chief Medical Director

Fort Myers, FL – Dermagenics U.S., Inc., a subsidiary of Greystone Pharmaceuticals Inc., today announces the appointment of I. Kelman Cohen, M.D. as Chief Medical Director.

Dr. Cohen has devoted the vast majority of his career to the problems of wound healing and treatment of chronic wounds. A graduate of Columbia University in New York and the University of North Carolina School of Medicine, he is board certified in General and Plastic Surgery. After two years of wound healing research at the National Institutes of Health he joined Virginia Commonwealth University in Richmond as Professor of Surgery where he established one of the world's most distinguished wound healing programs in clinical and laboratory research. He has edited a definitive text on the subject, published over 150 papers in major journals and lectured on the subject throughout the world. Clinician, educator, and applied researcher, his many awards include the Lifetime Achievement award from both the Wound Healing Society (a founding member) and the Society for Advancement of Wound Care.

Dr. Cohen states, “I took this position because working with Greystone affords me the opportunity to develop and bring to market exciting new products which will make a dramatic difference in the quality of life in patients with hard to heal wounds. The dynamic team at Greystone creates an environment that transforms research into reality. Greystone has the product technology to open a new era for the improvement of the health, happiness and well-being of patients with chronic wounds throughout the world. I am very pleased to be a member of the Greystone team.”

About Greystone

Founded in 1996, and currently headquartered in Fort Myers, Florida, with additional offices in Memphis, Tennessee, and Kaatsheuvel, the Netherlands, Greystone Pharmaceuticals is a medical products research and development company that has developed a proprietary advanced chronic wound care technology for the treatment of non-responsive wounds, particularly in diabetic patients. For more information about Greystone and its products, please visit: www.greystonepharmaceuticals.com.

-END-